NYSE:EBS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). More Details


Snowflake Analysis

Proven track record and fair value.


Similar Companies

Share Price & News

How has Emergent BioSolutions's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EBS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: EBS's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-0.05%

EBS

2.8%

US Biotechs

1.5%

US Market


1 Year Return

50.6%

EBS

27.3%

US Biotechs

22.3%

US Market

Return vs Industry: EBS exceeded the US Biotechs industry which returned 27.2% over the past year.

Return vs Market: EBS exceeded the US Market which returned 22.1% over the past year.


Shareholder returns

EBSIndustryMarket
7 Day-0.05%2.8%1.5%
30 Day-15.8%7.8%8.8%
90 Day-21.0%17.5%10.8%
1 Year50.6%50.6%29.5%27.3%25.1%22.3%
3 Year90.1%90.1%26.5%20.1%49.5%39.6%
5 Year145.8%130.0%21.0%12.7%105.8%83.3%

Long-Term Price Volatility Vs. Market

How volatile is Emergent BioSolutions's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Emergent BioSolutions undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EBS ($82.79) is trading below our estimate of fair value ($495.87)

Significantly Below Fair Value: EBS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: EBS is good value based on its PE Ratio (26x) compared to the US Biotechs industry average (27.9x).

PE vs Market: EBS is poor value based on its PE Ratio (26x) compared to the US market (19.4x).


Price to Earnings Growth Ratio

PEG Ratio: EBS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: EBS's PB Ratio (3.5x) is in line with the US Biotechs industry average.


Next Steps

Future Growth

How is Emergent BioSolutions forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-4.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EBS's earnings are forecast to decline over the next 3 years (-4.8% per year).

Earnings vs Market: EBS's earnings are forecast to decline over the next 3 years (-4.8% per year).

High Growth Earnings: EBS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: EBS's revenue is expected to decline over the next 3 years (-2.2% per year).

High Growth Revenue: EBS's revenue is forecast to decline over the next 3 years (-2.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EBS's Return on Equity is forecast to be high in 3 years time (21%)


Next Steps

Past Performance

How has Emergent BioSolutions performed over the past 5 years?

0.09%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EBS has a large one-off loss of $84.7M impacting its September 30 2020 financial results.

Growing Profit Margin: EBS's current net profit margins (12.5%) are higher than last year (0.5%).


Past Earnings Growth Analysis

Earnings Trend: EBS's earnings have grown by 0.09% per year over the past 5 years.

Accelerating Growth: EBS's earnings growth over the past year (3484.5%) exceeds its 5-year average (0.09% per year).

Earnings vs Industry: EBS earnings growth over the past year (3484.5%) exceeded the Biotechs industry -11.8%.


Return on Equity

High ROE: EBS's Return on Equity (13.3%) is considered low.


Next Steps

Financial Health

How is Emergent BioSolutions's financial position?


Financial Position Analysis

Short Term Liabilities: EBS's short term assets ($958.8M) exceed its short term liabilities ($299.3M).

Long Term Liabilities: EBS's short term assets ($958.8M) do not cover its long term liabilities ($1.1B).


Debt to Equity History and Analysis

Debt Level: EBS's debt to equity ratio (71.6%) is considered high.

Reducing Debt: EBS's debt to equity ratio has increased from 41.7% to 71.6% over the past 5 years.

Debt Coverage: EBS's debt is well covered by operating cash flow (46.1%).

Interest Coverage: EBS's interest payments on its debt are well covered by EBIT (10.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Emergent BioSolutions's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EBS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EBS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EBS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EBS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EBS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Bob Kramer (63 yo)

1.67yrs

Tenure

US$3,693,821

Compensation

Mr. Robert G. Kramer., also known as Bob, has been President at Emergent BioSolutions Inc. since March 26, 2018 and has been its Chief Executive Officer and Director since April 01, 2019. Mr. Kramer was Ch...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD3.69M) is about average for companies of similar size in the US market ($USD5.19M).

Compensation vs Earnings: Bob's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Fuad El-Hibri
Founder & Executive Chairman of the Board16.5yrsUS$3.01m2.12%
$ 93.1m
Robert Kramer
CEO, President & Executive Director1.67yrsUS$3.69m0.15%
$ 6.7m
Richard Lindahl
Executive VP2.75yrsUS$1.88m0.0075%
$ 327.8k
Atul Saran
Executive VP of Corporate Development3.58yrsUS$1.86m0.024%
$ 1.0m
Adam Havey
Executive Vice President of Business Operationsno dataUS$1.85m0.014%
$ 635.8k
Sean Kirk
Executive Vice President of Manufacturing & Technical Operations1.67yrsno data0.024%
$ 1.0m
Sharon Solomon
Senior VP & Chief Information Officerno datano datano data
Robert Burrows
Vice President of Investor Relations14.5yrsno datano data
Laura Kennedy
Senior VP and Chief Ethics & Compliance Officer4.25yrsno datano data
Lynn Kieffer
Vice President of Corporate Communicationsno datano datano data
Nina DeLorenzo
Senior Vice President of Global Communications & Public Affairs0.67yrno datano data
Katherine Strei
Executive VP of Human Resources & Chief Human Resources Officer4.92yrsno data0.053%
$ 2.3m

3.6yrs

Average Tenure

57yo

Average Age

Experienced Management: EBS's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Fuad El-Hibri
Founder & Executive Chairman of the Board16.5yrsUS$3.01m2.12%
$ 93.1m
Robert Kramer
CEO, President & Executive Director1.67yrsUS$3.69m0.15%
$ 6.7m
Louis Sullivan
Independent Director14.5yrsUS$709.73k0.046%
$ 2.0m
George Joulwan
Independent Director7.42yrsUS$688.00k0.035%
$ 1.5m
Ronald Richard
Lead Independent Directorno dataUS$781.00k0%
$ 0
Marvin White
Director0.17yrUS$83.66kno data
Jerome Hauer
Independent Director5.92yrsUS$705.00k0.0036%
$ 158.4k
Zsolt Harsanyi
Independent Director16.33yrsUS$770.00k0.031%
$ 1.3m
Sue Bailey
Independent Director13.5yrsUS$676.00k0.046%
$ 2.0m
Kathryn Zoon
Independent Director4.08yrsUS$686.00k0.0080%
$ 348.8k

7.4yrs

Average Tenure

69.5yo

Average Age

Experienced Board: EBS's board of directors are considered experienced (7.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.


Top Shareholders

Company Information

Emergent BioSolutions Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Emergent BioSolutions Inc.
  • Ticker: EBS
  • Exchange: NYSE
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.388b
  • Shares outstanding: 53.00m
  • Website: https://www.emergentbiosolutions.com

Number of Employees


Location

  • Emergent BioSolutions Inc.
  • 400 Professional Drive
  • Suite 400
  • Gaithersburg
  • Maryland
  • 20879
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EBSNYSE (New York Stock Exchange)YesCommon StockUSUSDNov 2006
ER4DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006
0IGALSE (London Stock Exchange)YesCommon StockGBUSDNov 2006

Biography

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 23:27
End of Day Share Price2020/12/04 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.